Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Checkpoint inhibitors in pancreatic cancer

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Checkpoint inhibitors in breast cancer - Current status

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. A systematic review of bevacizumab efficacy in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in several types of cancer. In this review we summarize published and ongoing studies on checkpoint inhibitors in pancreatic cancer (PC).

METHODS: We conducted a systematic literature search using Medline and Embase up to November 2018; additional data from a search on were included. Endpoints of interest encompassed overall survival (OS), progression free survival (PFS) and response rates.

RESULTS: Full-length articles constituted a minority of included records. Furthermore, few patients were enrolled, and only few phase II studies were identified. Disappointing limited activity was demonstrated with single-agent checkpoint inhibitors in PC. A small number of studies on combination therapy showed promise with regards to response. But overall, PC patients treated with checkpoint inhibitors were not shown to elicit improvement in response rates or overall survival.

CONCLUSION: Checkpoint inhibition monotherapy has failed to elicit efficacy in patients with pancreatic cancer. Combination regimens including chemotherapy have shown initial promise, but these results need to be verified. Numerous studies on checkpoint inhibition in PC are ongoing.

TidsskriftCancer Treatment Reviews
Sider (fra-til)17-30
Antal sider14
StatusUdgivet - aug. 2019

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

ID: 59155859